52
Participants
Start Date
August 22, 2022
Primary Completion Date
February 14, 2026
Study Completion Date
May 21, 2026
426c.Mod.Core-C4b 30 mcg
Administered via injection as a split dose into the deltoid muscle (both left and right).
426c.Mod.Core-C4b 100 mcg
Administered via injection as a split dose into the deltoid muscle (both left and right).
426c.Mod.Core-C4b 300 mcg
Administered via injection as a split dose into the deltoid muscle (both left and right).
Placebo
Administered via injection as a split dose into the deltoid muscle (both left and right).
BG505
A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
Columbia P&S CRS, New York
Alabama CRS, Birmingham
Bridge HIV CRS, San Francisco
Seattle Vaccine and Prevention CRS, Seattle
The Ponce de Leon Center CRS, Atlanta
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
National Institute of Allergy and Infectious Diseases (NIAID)
NIH